(Q38011312)

English

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease

scientific article published on May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

meningococcal vaccine

1 reference

based on heuristic

inferred from title

author name string

Peter M Dull

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

E David McIntosh

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

30 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

B18-25

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Reverse vaccinology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Use of meningococcal vaccines in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Efficacy of meningococcal vaccine and barriers to vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

The epidemiological impact of antimeningococcal B vaccination in Cuba

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Review of meningococcal group B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Functional significance of factor H binding to Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

NadA, a novel vaccine candidate of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningoc

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.062

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.01.062

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38011312&oldid=2151953023"